• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Mumbai, July 17

Glenmark Pharmaceuticals Ltd’s prospective pain-related molecule, GRC 10693, is set to enter its first phase of human trials. The molecule has been filed for Phase I approval with European regulatory authorities, a note from the company said. Further, it added that Glenmark expects to complete Phase I trials for GRC 10693 and initiate Phase II trials before the end of fiscal 2009. Phase I trials involve the first exposure of the prospective drug molecule to a small g roup of healthy human volunteers, to evaluate safety and the safe dosage range of the drug. In Phase II trials, the sample size gets bigger and the prospective drug is exposed to people with the illness that the drug candidate targets. This is Glenmark’s fifth molecule to enter clinics from its pipeline of 13 new chemical and biological entities, said Mr Glenn Saldanha, Managing Director and Chief Executive, in a statement from the company. The company’s prospective drug candidate targets neuropathic pain, osteoarthritis and other inflammatory pain. According to industry data, the neuropathic pain market is estimated at $5 billion with over 40 million patients worldwide, while the osteoarthritis market is valued at over $4 billion with over 20 million patients.

– Our Bureau

More Stories on : Research & Development | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Hindustan Copper’s Ghatsila rail network on a modernisation track

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line